Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

drug side effects

This page shows the latest drug side effects news and features for those working in and with pharma, biotech and healthcare.

GSK sells eczema and psoriasis drug to Dermavant for £250m

GSK sells eczema and psoriasis drug to Dermavant for £250m

that could provide an alternative to topical and oral steroids, which have side effects. ... In phase II trials the drug had a dose-dependent impact on plaque psoriasis lesions, and it is ready to move to phase III testing.

Latest news

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    ViiV’ s two-drug HIV combo backed by CHMP. The committee also backs two biosimilar medicines. ... At the moment most patients are treated with three-drug regimens, and ViiV says the two-drug regimens can reduce drug exposure and side effects, as well

  • It’s only money It’s only money

    drug by emphasising potential side effects. ... It is suspected that falsified data was used in the clinical trial of Novartis’s best selling drug Diovan.

  • BMS' Yervoy picks up another indication in Europe BMS' Yervoy picks up another indication in Europe

    found to be more effective than Yervoy with patients reporting a better PFS with fewer side effects. ... The European approval follows a decision by the US Food and Drug Administration’s (FDA) to approve the drug for the same indication back in July

  • Shire’s Maribavir wins US breakthrough therapy designation Shire’s Maribavir wins US breakthrough therapy designation

    The US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to Shire’s investigational treatment for cytomegalovirus (CMV) infection in transplant patients. ... Despite existing antiviral therapies for this disease area,

  • GSK’s ViiV gets US okay for two-drug HIV regimen GSK’s ViiV gets US okay for two-drug HIV regimen

    GSK’ s ViiV gets US okay for two-drug HIV regimen. Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant. ... quickly. It has been trying to develop two-drug regimens that can reduce drug exposure and side effects, as well as improve

More from news
Approximately 1 fully matching, plus 106 partially matching documents found.

Latest Intelligence

  • Redirecting your patient strategy Redirecting your patient strategy

    But when people are dealing with their condition for so long, it is important that you understand how they're actually managing it, how they're using the drug.”. ... These new companies have developed novel business models based on sharing the data and

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    IIs are more potent, with fewer side effects and drug interactions and the top reason for prescribing them is their good tolerability profile. ... As patients differ so do their barriers to adherence, whether this be complexity of the dosing regimen,

  • Patients First Patients First

    to their thoughts on the impact of drug side effects, these are all areas that pharma is already actively engaged with at some level.

  • Patients First Patients First

    to their thoughts on the impact of drug side effects, these are all areas that pharma is already actively engaged with at some level.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    The G-BA assesses drugs on four criteria: mortality; morbidity (for example, symptom improvement); quality of life; and adverse events (toxicity and side effects). ... A natural question to ask is how the benefit finding impacts the final price of a drug

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • What does social media listening actually tell us?

    They have experiences, opinions and ideas which could be used to improve both treatments and practices (such as reports of side effects and effective drug combinations, for example) – and the methods ... The limits and regulations which accompany the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Quick links

Infographics

Multimedia